Drugs
Researchers at T Cell Sciences, Inc. have reported positive outcomes from the company's first Phase I clinical trial of TP10, a soluble form of complement receptor 1 (sCR1), in patients at risk for Adult Respiratory Distress Syndrome (ARDS). The trial involved 24 patients with acute lung injury arising
Pharmaceutical industry
Lynx Therapeutics Inc., a Hayward, California-based company, has announced a partnership with Hoechst Marion Roussel, the global pharmaceutical division of Hoechst AG, to provide access to its Massively Parallel Signature Sequencing (MPSS) technology. Under the agreement, Lynx will receive research and development support, as well as equity capital, in exchange
Drugs
TheraTech Inc. and Wyeth-Ayerst International Inc., a division of American Home Products Corp., have entered into an agreement to market TheraTech's testosterone transdermal patch in Mexico, Central and South America, non-French-speaking Africa, and the Middle East. The patch is intended for the treatment of male hypogonadism, a condition
Drugs
Collagen Corp. has made a significant announcement in its effort to expand its marketing franchise in cosmetic medicine. The company has acquired LipoMatrix Inc., the developer and manufacturer of the Trilucent breast implant, and will be taking a non-recurring charge for in-process research and development. This charge, valued at approximately
Pharmaceutical industry
Hoechst Marion Roussel, the global pharmaceutical division of Hoechst AG, has signed a gene therapy collaboration with Cell Genesys, Inc., a biotechnology company based in California. The initial focus of the collaboration is the research and development of gene therapy technologies and products for acquired immune deficiency syndrome (AIDS). This
Pharmaceutical industry
Biopharmaceutical company Somatogen, Inc. announced on September 18, 1995, that it has filed a Registration Statement with the Securities and Exchange Commission for a proposed public offering of 2,500,000 shares of Common Stock. The company intends to use the net proceeds from the offering to fund recombinant hemoglobin
Pharmaceutical industry
Somatogen, a biopharmaceutical company, has announced the receipt of a $2 million equity milestone payment from Eli Lilly and Company. This payment is related to the completion of enrollment in two early Phase II clinical trials of OptroTM, a recombinant human hemoglobin product. The payment is a significant development in
Drugs
Foster City, Calif.--(HealthWire)--Sept. 18, 1995--Gilead Sciences, Inc. (Nasdaq: GILD) announced today the presentation of interim data from a randomized, controlled pivotal study indicating that VISTIDE(TM) (cidofovir intravenous) delayed the time to progression of retinitis in patients with relapsing CMV retinitis, when compared to historical controls. Prior
Drugs
ImmuLogic Pharmaceutical Corp., a biotechnology company, has announced a public offering of 2,400,000 shares of its common stock at a price of $10.75 per share, generating gross proceeds of $25,800,000. The company plans to utilize the proceeds for product research, development, and manufacturing, as well
Drugs
Collagen Corp., a technology-based company based in Palo Alto, has filed an amended complaint in its lawsuit against Matrix Pharmaceutical Inc. for allegedly stealing trade secrets. The amended complaint names two former Collagen employees as additional defendants, Steven W. Carlson and Daniel R. Prows, who allegedly took proprietary manufacturing process
Pharmaceutical industry
Cell Genesys, Inc. has completed patient enrollment for the Phase I portion of its initial trial of anti-HIV T cell gene therapy for AIDS. The company's novel therapy involves genetically modifying killer T cells from the human immune system to treat viral infection and cancer. The trial, which
Pharmaceutical industry
TAP Holdings Inc. has entered into a licensing agreement with RPMS Technology Ltd. to develop and commercialize compounds that have shown potent in vitro activity against Helicobacter pylori (H. pylori) bacteria. H. pylori infection has been linked to gastric-related conditions, including ulcers and gastric carcinoma. The agreement grants TAP exclusive
